Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: Rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial

American Heart Journal

Volumn 156, Issue 4, 2008, Pages 623-632

  Califf, Robert M ^a,b   Boolell, Mitradev ^c   Haffner, Steven M ^d   Bethel, M Angelyn ^b   McMurray, John ^e   Duggal, Anil ^c   Holman, Rury R ^f  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NATEGLINIDE; PLACEBO; VALSARTAN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; FAT INTAKE; FEMALE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL ACTIVITY; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STROKE; UNSTABLE ANGINA PECTORIS; WEIGHT REDUCTION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CYCLOHEXANES; DIABETIC ANGIOPATHIES; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; GLUCOSE INTOLERANCE; HUMANS; HYPOGLYCEMIC AGENTS; LIFE STYLE; OUTCOME ASSESSMENT (HEALTH CARE); PHENYLALANINE; RESEARCH DESIGN; TETRAZOLES; VALINE;

EID: 52949093903     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2008.05.017     Document Type: Article

References (46)

1. King H., Aubert R.E., and Herman W.H. Global burden of diabetes, 1995-2025. Prevalence, numerical estimates, and projections. Diabetes Care 21 (1998) 1414-1431
2. Harris M.I., Flegal K.M., Cowie C.C., et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. Diabetes Care 21 (1998) 518-524
3. Zimmet P., Alberti K.G., and Shaw J. Global and societal implications of the diabetes epidemic. Nature 414 (2001) 782-787
4. McGuire D.K., and Granger C.B. Diabetes and ischemic heart disease. Am Heart J 138 (1999) S366-S375
5. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
6. Nathan D.M., Cleary P.A., Backlund J.Y., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353 (2005) 2643-2653
7. Chiasson J.L., Josse R.G., Gomis R., et al., STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290 (2003) 486-494
8. Tuomilehto J., Lindstrom J., Eriksson J., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344 (2001) 1343-1350
9. The Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002) 393-403
10. Bethel M.A., Holman R., Haffner S.M., et al. Determining the most appropriate components for a composite clinical trial outcome. Am Heart J 156 (2008) 633-640
11. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 22 (1999) S5-S19
12. Alberti K.G.M.M., Zimmet P.G., and for the WHO Consultation. Definition, diagnosis, and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus (1999), World Health Organization, Geneva
13. Weyer C., Bogardus C., Mott D.M., et al. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104 (1999) 787-794
14. Efendic S., Luft R., and Wajngot A. Aspects of the pathogenesis of type 2 diabetes. Endocrine Rev 5 (1984) 395-410
15. Novartis Pharmaceutical Corp. Nateglinide prescribing information. Available at:. http://www.starlix.com/starlix/medias/pdfs/us_starlix_pi.pdf Last accessed May 7, 2003
16. Gribble F.M., Manley S.E., and Levy J.C. Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166). Diabetes Care 24 (2001) 1221-1225
17. Vermes E., Ducharme A., Bourassa M.G., et al. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the studies of left ventricular dysfunction (SOLVD). Circulation 107 (2003) 1291-1296
18. Hansson L., Lindholm L.H., Niskanen L., et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 353 (1999) 611-616
19. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 (2002) 145-153
20. The ALLHAT Investigators. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. JAMA 288 (2002) 2981-2997
21. Vermes E., Ducharme A., Bourassa M.G., et al. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation 107 (2003) 1291-1296
22. Lindholm L.H., Ibsen H., Borch-Johnsen K., et al., for the LIFE Study Group. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 20 (2002) 1879-1886
23. Hansson L., Lithell H., and on behalf of the SCOPE Study Investigators. The Study on COgnition and Prognosis in Elderly Hypertensives (SCOPE). Presented at the Joint 19th Scientific Meeting of the International Society of Hypertension and 12th European Meeting on Hypertension, Prague, Czech Republic, June 23-27 (2002)
24. Yusuf S., Ostergren J.B., Gerstein H.C., et al., for the CHARM Investigators. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation 112 (2005) 48-53
25. Julius S., Kjeldsen S.E., Weber M., et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363 (2004) 2022-2031
26. Bosch J., Yusuf S., Gerstein H., et al. Effect of ramipril on the incidence of diabetes. N Engl J Med 355 (2006) 1551-1562
27. Paolisso G., Tagliamonte M.R., Gambardella A., et al. Losartan mediated improvement in insulin action is mainly due to an increase in non-oxidative glucose metabolism and blood flow in insulin-resistant hypertensive patients. J Hum Hypertens 11 (1997) 307-312
28. Top C., Cingozbay B.Y., Terekeci H., et al. The effects of valsartan on insulin sensitivity in patients with primary hypertension. J Int Med Res 30 (2002) 15-20
29. Lindholm L.H., Persson M., Alaupovic P., et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 21 (2003) 1563-1574
30. Wing L.M., Reid C.M., Ryan P., et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 348 (2003) 583-592
31. Holwerda N.J., Fogari R., Angeli P., et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J Hypertens 14 (1996) 1147-1151
32. Novartis Pharmaceutical Corp. Diovan (valsartan) prescribing Information. Available at:. http://www.pharma.us.novartis.com/product/pi/pdf/diovan.pdf Last accessed May 7, 2003
33. Cohn J., and Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 (2001) 1667-1675
34. Black H.R., Davis B., Barzilay J., et al. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care 31 (2008) 353-360
35. National Heart, Lung, and Blood Institute. ACCORD telebriefing prepared remarks. February 6, 2008. Available at:. http://www.nhlbi.nih.gov/health/prof/heart/other/accord/index.htm Last accessed April 9, 2008
36. Dormandy J.A., Charbonnel B., Eckland D.J., et al., for the PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
37. Califf RM, DeMets DL. Lessons learned from recent cardiovascular clinical trials. Parts I and II. Circulation 2002;106:746-51 and 880-6.
38. Balkau B., Shipley M., Jarret R.J., et al. High blood glucose concentration is a risk factor for mortality in middle-aged men: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 21 (1998) 360-367
39. Coutinho M., Wang Y., Gerstein H.C., et al. The relationship between glucose and incident cardiovascular events. Diabetes Care 22 (1999) 233-240
40. Pyörälä K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 2 (1979) 131-141
41. DECODE Study Group, and on behalf of the European Diabetes Epidemiology Study Group. Glucose tolerance and mortality: comparison of WHO criteria and American Diabetic Association diagnostic criteria. Lancet 354 (1999) 617-621
42. Inzucchi S.E. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 287 (2002) 360-372
43. DeFronzo R.A. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 131 (1999) 281-303
44. Keech A., Simes R.J., Barter P., et al., for the FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1849-1861
45. Psaty B.M., and Rennie D. Stopping medical research to save money: a broken pact with researchers and patients. JAMA 289 (2003) 2128-2130
46. Dargie H.J. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 357 (2001) 1385-1390